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In population studies, high-density lipoprotein cholesterol (HDL-C) is inversely related to the risk of myocardial infarc-
tion and death.1–4 Of note, in patients fully treated according to 
current guidelines with intense statin therapy and low-density 
lipoprotein cholesterol (LDL-C) at target levels, HDL-C re-
mains predictive of outcome for major adverse cardiovascular 
events.5 Accordingly, the metabolism and the vascular effects 
of HDL have attracted enormous interest. Furthermore, HDL 
is being intensely investigated as a potential therapeutic target 
in patients at high cardiovascular risk. In line with a causally 
protective effect, HDL can exert a broad spectrum of antiath-
erogenic effects capable of halting or even reversing athero-
sclerosis in several animal models, in particular by transgenic 
overexpression or exogenous application of apolipoprotein 
A-I (apoA-I), the most abundant protein of HDL.6
Unfortunately, it has been proven difficult to reduce coro-
nary risk with drugs increasing HDL-C, such as fibrates, nia-
cin, or inhibitors of cholesteryl ester transfer protein (CETP), 
beyond that achieved with statin therapy alone.7–10 Moreover, 
in several inborn errors of human HDL metabolism and ge-
netic mouse models with altered HDL metabolism, the chang-
es in HDL-C levels were not associated with accompanying 
changes in cardiovascular risk or atherosclerotic plaque load, 
respectively, as has been expected from epidemiological stud-
ies.11–13 Thus, the pathogenic role and, hence, suitability of 
HDL as a therapeutic target has increasingly been questioned. 
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In fact, it has been argued that low HDL-C may only repre-
sent a marker for proatherogenic risk factors, rather than HDL 
being a mediator protecting against atherogenesis. However, 
although not disputed, such a conclusion neglects the struc-
tural and functional heterogeneity of HDL, which is neither 
reflected by the nonfunctional clinical biomarker HDL-C nor 
has yet been targeted by randomized controlled trials7–10 or 
Mendelian randomization studies.13,14
Structure of HDL
In a prototypic HDL particle, 2 to 5 molecules of apoA-I and 
≈100 molecules of phosphatidylcholine form an amphipathic 
shell in which several molecules of unesterified cholesterol are 
imbedded surrounding a core of completely water-insoluble 
cholesterol esters.15 Molar differences in the content of major 
proteins and lipid constituents of HDL, that is apoA-I, phospha-
tidylcholine, sphingomyelin, cholesterol, and cholesteryl es-
ters, cause considerable heterogeneity of HDL as delineated by 
electron microscopy (shape), ultracentrifugation (density), gel 
filtration, polyacrylamide gel electrophoresis, nuclear magnetic 
resonance spectroscopy (size), charge (agarose gel electropho-
resis), or affinity (apolipoprotein composition).16 Unfortunately, 
there is only limited overlap between the proposed HDL sub-
classes defined by the various isolation methods. To facilitate 
communication and application in clinical studies, a consensus 
group has suggested 5 HDL subclasses according to size (small, 
very small, medium, large, very large).16 To date, clinical and 
epidemiological studies have come to discrepant conclusions 
on the prognostic performance of HDL subclasses.16–18
This macroheterogeneity is further increased by different 
quantities of proteins or lipids, some of which may contrib-
ute to the pleiotropic functions of HDL. HDL particles carry 
>80 different proteins19–21 and hundreds of lipid species.19,22 
Most recently, even microRNAs have been found in HDL par-
ticles,23 although a relevant uptake of microRNAs from HDL 
into vascular cells was not observed.24 Many of these mole-
cules are not passive cargo but biologically active and contrib-
ute to pleiotropic and antiatherogenic properties of HDL. Of 
note, these molecules are not only involved in lipid transport 
and metabolism (ie, apoA-I, apoA-II), but also in oxidation 
or antioxidation (eg, paraoxonase), innate immune defense 
(eg, lipopolysaccharide-binding protein, clusterin, apoL1), or 
regulation of cell survival, proliferation, and migration (eg, 
sphingosine-1-phosphate [S1P], clusterin). Importantly, the 
plasma concentration of many microcomponents is by 1 or 2 
orders of magnitude lower than that of HDL particles (10–20 
μmol/L). Accordingly, they are not equally distributed among 
HDL subclasses. Interestingly, such microcomponents seem 
to accumulate in the smallest HDL particles (ie, HDL3).20 
At first sight, this is in contrast to their small size. However, 
HDL3 particles are present in plasma at the highest concentra-
tion, which is considerably higher than that of its microcom-
ponents, suggesting that they are not residing on the same but 
on different particles.
Of note, this microheterogeneity of HDL particles of healthy 
subjects is even more pronounced in patients with inflammato-
ry diseases, diabetes mellitus, coronary artery disease (CAD), 
or chronic kidney disease because of loss or structural modi-
fication of HDL constituents or by the acquisition of atypical 
constituents.25–31 Several of these changes have been associated 
with a loss of vasoprotective functions, such as loss of the abil-
ity to stimulate cholesterol efflux after chlorination or nitration 
of tyrosine residues in apoA-I,32 loss of the ability to inhibit 
endothelial apoptosis,28 or loss of the ability to induce endothe-
lium-dependent vasodilation after lipid peroxidation.26 HDL 
may even acquire properties adverse to endothelial function, 
for example, by accumulation of malondialdehyde or symmet-
rical dimethylarginine.27,29 Symmetrical dimethylarginine was 
shown to modify HDL such that it is recognized by toll-like 
receptor-2, leading to inhibition of endothelial NO synthase 
(eNOS)-activating pathways, stimulation of NADPH oxidase, 
impaired endothelial repair, increased proinflammatory activa-
tion, and increased arterial blood pressure.29
The very discrepant concentrations of HDL-C (>1 mmol/L), 
compared with apoA-I (≈50 μmol/L), or minor bioactive com-
ponents of HDL (eg, PON1 or clusterin, 1 μmol/L; S1P, 0.5 
μmol/L; apoL1, 0.1 μmol/L), or modifications of HDL (mi-
cromoles per liter or less), would predict the lack of sensitiv-
ity and specificity of plasma levels of HDL-C and apoA-I to 
reflect changes in structure–function relationships of HDL in 
healthy subjects and patients with cardiovascular disease.
Thus, depending on the mode of action, therapeutic interven-
tions in HDL metabolism will either reduce or further increase 
the structural heterogeneity of HDL beyond what can be mea-
sured by conventional HDL-C or apoA-I assays. Functional 
HDL high-throughput assays that assess structure–function re-
lationships of HDL in health and disease as well as after thera-
peutic interventions need to be developed (eg, multiparametric 
measurements of HDL-associated proteins by single-reaction 
monitoring mass spectrometry or arrayed immunoassays and 
delineation of lipid species). The ability to make such measure-
ments could lead to the discovery of components that are more 
closely associated with cardiovascular risk and treatment effects, 
compared with plasma concentrations of HDL-C and apoA-I.
Metabolism of HDL
The majority of HDL particles originate from lipid-free or 
poorly lipidated apoA-I that is secreted by hepatocytes and the 
intestinal mucosa, or dissociate from lipolysed chylomicrons 
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and very low-density lipoproteins as well as from intercon-
verting mature HDL particles.11,33 The interaction of lipid-free 
or poorly lipidated apoA-I, the so-called pre-β1-HDL, with 
the ATP-binding cassette transporter A1 (ABCA1) leads to ef-
flux of phospholipids and unesterified cholesterol from many 
cells, including hepatocytes, enterocytes, and macrophages, 
and to the formation of small discoidal HDL particles, called 
α4-HDL. These HDL precursors can continue to induce lip-
id efflux from cells, for example, via scavenger receptor BI 
(SR-BI) or ATP-binding cassette transporter G1 (ABCG1).33 
The effluxed cholesterol and phosphatidylcholine serve as 
substrates of lecithin/cholesterol acyltransferase (LCAT) to 
form water-insoluble cholesteryl esters, which form the core 
of mature spherical HDL. These initially small α-HDL3 par-
ticles become larger α-HDL2 particles through ongoing acqui-
sition of phospholipids and cholesterol from both cells (eg, 
via interactions with SR-BI or ABCG1) and apoB-containing 
lipoproteins and fusion with other HDL particles. The lat-
ter 2 processes involve the activity of phospholipid transfer 
protein.11,33 The catabolism of HDL differs from that of LDL 
because only a minor proportion of HDL seems to be elimi-
nated by holoparticle uptake into cells. In this as-yet-poorly-
understood pathway, a high-affinity interaction of apoA-I with 
ectopic F0F1–ATPase leads to the formation of ADP, which 
activates purinergic receptors to induce the uptake of HDL by 
an as-yet-unidentified low-affinity HDL receptor.34–36
The 2 better-characterized pathways mediate the removal of 
lipids from HDL independently of its protein moiety: CETP 
exchanges triglycerides of apoB-containing lipoproteins for 
cholesteryl esters of HDL, which are ultimately eliminated 
via the LDL receptor pathway, and SR-BI mediates the se-
lective uptake of HDL lipids into the liver and steroidogenic 
organs.11,33 The removal of cholesteryl esters by CETP and 
SR-BI, as well as the lipolysis of triglycerides and phospho-
lipids by hepatic lipase and endothelial lipase, respectively, 
leads to the conversion of HDL2 into HDL3 as well as the gen-
eration of pre-β1-HDL.11,33 This lipid-free or lipid-poor apoA-I 
either regenerates mature HDL by inducing ABCA1-mediated 
lipid efflux from various cells, or is filtrated through the renal 
glomeruli. In the proximal tubule of the kidneys, apoA-I is 
endocytosed by the cubilin and megalin receptors and targeted 
for lysosomal degradation.37
Cholesterol Efflux and Reverse  
Cholesterol Transport
Reverse cholesterol transport (RCT)33 describes the trans-
port of excess cholesterol from peripheral cells to the liver 
for excretion into the bile, either directly or indirectly after 
conversion into bile acids, or to adrenals, testes, and ovaries 
for steroid hormone production. In the classical model, HDL 
particles are considered passive acceptors of cellular choles-
terol, in which LCAT-mediated esterification prevents equili-
bration of cholesterol between cell membranes and HDL, 
thereby allowing net cholesterol efflux.38 Because of the RCT 
model, it is still erroneously thought that HDL-C levels re-
flect the amount of cholesterol released from peripheral cells 
and transported by HDL back to the liver. The discovery of 
several rate-limiting genes and the metabolic characterization 
of patients and genetic mouse models that lack these limiting 
factors have led to significant revisions of the RCT model and 
ruled out that HDL-C levels reflect the activity of RCT.33
In addition to Glomset aqueous diffusion, cholesterol ef-
flux is facilitated by tethering of HDL to SR-BI and ABCA1- 
or ABCG1-facilitated transport to mediate the active export 
of excess cholesterol to α-HDL (SR-BI and ABCG1) and 
lipid-poor apoA-I (ABCA1).33 The transporters ABCA1 
and ABCG1 are integrated into both positive feed-forward 
and negative feedback regulation loops. Cellular lipid over-
load leads to the formation of oxysterols, which activate 
nuclear liver X receptors α and β to induce the transcription 
of ABCA1 and ABCG1 and hence cholesterol efflux.39 It is 
presently not clear how ABCG1 facilitates sterol transport 
to acceptors at the cell surface, because it was reported to be 
an intracellular transporter.40 Nonetheless, there is no contro-
versy about its role in promoting cholesterol efflux.33 Several 
microRNAs, for example, miR33, miR122, and miR144, de-
crease the production of ABCA1 and hence reduce cholesterol 
efflux.41–43 Thus, cholesterol efflux is determined by the ex-
tracellular concentration and composition of HDL particles 
as well as by the activity of ABC transporters. By finetuning 
cellular cholesterol homeostasis, cholesterol efflux by apoA-I/
ABCA1- and HDL-mediated efflux in concert with ABCG1 
exerts important regulatory steps on many cellular functions, 
including proliferation and mobilization of hematopoietic 
stem cells.43 ATP-binding cassette transporter G4–mediated 
cholesterol efflux to HDL regulates megakaryocyte prolif-
eration.44 Cholesterol efflux also regulates the inflammatory 
responses of monocytes and macrophages,45 expansion of 
lymphocytes,46 NO production by eNOS,47 and insulin secre-
tion from pancreatic β-cells.48 To test the relevance of choles-
terol efflux in clinical studies, bioassays have been developed 
to quantify cellular cholesterol efflux activity of fibroblasts or 
monocytes, cholesterol acceptor capacity of HDL, and total 
or apoB-depleted serum or plasma from patients. Studies in 
families with inborn errors of HDL metabolism confirmed the 
feasibility of these bioassays; that is, cholesterol efflux in total 
or apoB-depleted plasmas from patients with apoA-I, LCAT, 
or ABCA1 deficiency is strongly reduced and cholesterol ef-
flux from fibroblasts and monocytes carrying mutations in 
ABCA1 is decreased in a gene dosage–dependent fashion.49,50 
Measurements of cholesterol efflux of total or apoB-depleted 
plasmas have been used in clinical and epidemiological stud-
ies, however with conflicting results.51 Characterization of in-
terferences and disturbances by the sample specimens used, 
as well as standardization of preanalytical and analytic proce-
dures, is needed for further exploitation of cholesterol efflux 
capacity as a biomarker in drug development.51
Despite the pivotal role of apoA-I and ABCA1 for choles-
terol efflux and HDL formation, mice deficient of ABCA1 or 
apoA-I excrete normal amounts of sterols in their feces with 
no disturbances in body cholesterol homeostasis.52 Moreover, 
both transplantation of ABCA1-deficient bone marrow cells 
and targeted knockout of ABCA1 in macrophages in mice 
showed that cholesterol efflux from macrophages does not 
directly affect HDL-C plasma levels.53,54 Such incompat-
ibilities with Glomset RCT model were partially resolved by 
the concept of macrophage-specific RCT and its validation 
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in a novel experimental animal model: peritoneal or bone 
 marrow–derived macrophages loaded with radioactive cho-
lesterol were installed into the peritoneum of recipient mice 
to record the uptake of radioactive cholesterol into the plasma 
and liver as well as its excretion into feces.55,56 Fecal excretion 
of macrophage-derived radioactive sterols was found to be de-
creased by the knockout of ABCA1 or apoA-I and increased by 
the overexpression of apoA-I. By applying this experimental 
procedure to genetic animal models, the  importance of several 
rate-limiting genes in RCT was verified (ie, apoA-I, ABCA1, 
ABCG1, SR-BI, or CETP), but also refuted (LCAT).55,56 Novel 
bottlenecks of RCT (eg, intestinal cholesterol resorption by 
NPC1L1) were identified using this model.57 It also contrib-
uted to the growing evidence for the existence of a liver- and 
HDL-independent RCT pathway, the so-called transintesti-
nal cholesterol excretion.58 Notably, compared with HDL-C 
levels, the activity of macrophage-specific RCT also showed 
stronger correlations with atherosclerosis in different animal 
models with disturbed HDL metabolism.56 Unfortunately, 
macrophage-specific RCT in humans could not be assessed as 
yet. In clinical studies, measurement of fecal sterol excretion or 
the recently described isotopic dilution method does not distin-
guish macrophage-specific RCT from general RCT.59
Vascular Protective Effects of HDL
HDL from healthy subjects can exert several protective ef-
fects in the vasculature and, in particular, on endothelial cells 
(Figure 1). Of note, HDL from healthy subjects stimulates NO 
release from human aortic endothelial cells in culture (Figure 2) 
and increases the expression of eNOS.27,60–62 Furthermore, 
it suppresses the expression of adhesion molecules, such as 
vascular cell adhesion molecule 1, and inhibits the adhesion 
of white blood cells.25,63 HDL also exerts antithrombotic ef-
fects because it reduces tissue factor expression in endothelial 
cells exposed to cytokines and reduces platelet activation.64 
Furthermore, in the mouse carotid artery model, HDL enhanc-
es endothelial repair after vascular injury.27 Finally, HDL ob-
tained from healthy subjects induced expression of Bcl-xL, the 
endothelial antiapoptotic Bcl-2 protein, and reduced endothe-
lial cell apoptosis in vitro and in apoE-deficient mice in vivo.28
Such effects are seen not only in vitro and in animal mod-
els in vivo, but also in patients with mutations in ABCA1.65 In 
patients with hypercholesterolemia, infusion of reconstituted 
HDL particles consisting mainly of apoA-I and phospholipids 
(and thus resembling pre-β1HDL)66 almost doubles HDL-C 
plasma levels and improves impaired endothelial function as 
assessed by intra-arterial infusion of acetylcholine and mea-
surement of forearm blood flow by plethysmography or high-
resolution ultrasound of the brachial artery and flow-mediated 
vasodilation, respectively (Figure 3).66 Furthermore, in patients 
with CAD, weekly intravenous infusions of apoA-1Milano, a 
genetic variant of apoA-I with maintained or even improved 
functionality,67 at dosages of 15 or 45 mg/kg body weight re-
duced coronary plaque volume as assessed by intravascular ul-
trasound.68 It is to be noted that no dose–response relationship 
was notable in this pilot study. Infusion of ApoA-I neither ame-
liorated endothelial function in patients with acute coronary 
syndrome (ACS)69 nor affected the plaques.70
Several agonists and receptors in HDL and endothelial 
cells, respectively, have been identified that are thought to me-
diate the vasoprotective effects of HDL; both NO-dependent 
and NO-independent mechanisms have been described. HDL 
was shown to activate eNOS by regulating the cholesterol 
homeostasis of caveolae, where eNOS is localized. In this 
respect, ABCG1 was identified as an important cellular me-
diator of these effects by facilitating efflux of cholesterol and 
Figure 1. Proposed direct vascular protective 
and potentially antiatherogenic effects of normal 
high-density lipoprotein (HDL).
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Figure 2. Effects of high-density lipoprotein obtained from 
healthy subjects, patients with coronary artery disease (CAD) 
or acute coronary syndrome on NO release from human 
aortic endothelial cells. Modified and adapted from Besler 
et al.27 Authorization for this adaptation has been obtained both 
from the owner of the copyright in the original work and from the 
owner of copyright in the translation or adaptation.
 at Universitaet Zuerich on January 28, 2015http://circres.ahajournals.org/Downloaded from 
Lüscher et al  HDL Protective Effects, Dysfunction, and Therapy  175
7-ketocholesterol.47 SR-BI was also found to be important for 
sensing the cholesterol concentration in plasma membrane do-
mains of endothelial cells and enterocytes, independent of its 
ability to bind HDL or mediate cholesterol efflux.71 Other lab-
oratories provided evidence both in vitro and in vivo that S1P 
carried by HDL induces eNOS phosphorylation by binding to 
S1P1 and S1P3 receptors and thereby activating PI3 kinase 
and Akt phosphorylation. In fact, mice lacking either S1P3 or 
the S1P-binding protein apoM and thereby S1P showed re-
duced NO production as well as NO-dependent vasodilation 
and junction closure.72,73 Several agonists and receptors have 
also been identified, which promote endothelial integrity by 
eNOS-independent mechanisms. S1P associated with HDL 
was found to stimulate endothelial junction closure and to in-
hibit apoptosis.74,75 Interaction of HDL with SR-BI was found 
to stimulate proliferation and migration of endothelial cells 
by signaling through its PDZ domain to small G-proteins.76 
Interaction of apoA-I with ectopic β-ATPase leads to the gen-
eration of ADP, which in turn activates a purinergic receptor 
to stimulate endothelial cell proliferation.34 Furthermore, clus-
terin is an antiapoptotic agonist carried by HDL, which stimu-
lates Akt phosphorylation and thereby inhibits cell death.28 It 
is not yet clear whether these mechanisms operate in a parallel 
or integrated manner. In agreement with the latter concept, it 
has been suggested that by tethering HDL on endothelial cell, 
SR-BI facilitates the interaction of S1P with its receptors,77 
raising the possibility that SR-BI–mediated effect on eNOS 
may, at least partially, be mediated by S1P. Alternatively, 
HDL may promote S1P efflux from endothelial cells, which 
is known to involve the ATP-binding cassette transporter C1 
and which would explain why initially S1P-free reconstituted 
HDL particles are able to stimulate eNOS phosphorylation.78
HDL Dysfunction in Cardiovascular Patients
The vascular effects exerted by HDL obtained from patients 
with a range of cardiovascular conditions differ substantially 
from the properties of HDL obtained from healthy subjects, 
termed HDL dysfunction.79 Unlike HDL from healthy sub-
jects, HDL from patients with diabetes mellitus, CAD, ACS, 
or chronic renal dysfunction no longer simulates NO release 
from endothelial cells in culture, but rather tends to inhibit it 
(Figure 2).26,27,29 Similarly, inhibition of endothelial vascular 
cell adhesion molecule 1 expression as well as the adhesion of 
white blood cells to activated endothelial cells observed in HDL 
from healthy subjects is markedly reduced or absent, similar 
to the endothelial antiapoptotic effects when HDL of patients 
with stable CAD, or of patients with ACS, are examined.25,27,28
One of the molecular mechanisms of this so-called HDL 
dysfunction in patients with CAD is a reduced activity (in the 
presence of an increased protein level) of HDL-associated 
paraoxanase-1 (PON-1), which normally prevents HDL from 
oxidative modification (Figure 4). A reduced HDL-associated 
activity of PON-1 leads to the generation of modified HDL with 
endothelial PKCβ2-activating properties, at least in part be-
cause of increased formation of malondialdehyde.27 In contrast 
to HDL from healthy subjects, HDL from patients with CAD 
gains access to endothelial lectin-like oxidized LDL  receptor-1 
and activates PKCβ2, which in turn leads to the inhibition of 
eNOS activation because of its phosphorylation at the inhibi-
tory residue T495 rather than at its activating residue S1177. 
This eventually contributes to a loss of  anti-inflammatory ef-
fects and endothelial repair capability of HDL.
Similarly, HDL from patients with CAD or ACS does not 
 inhibit endothelial apoptosis because it fails to activate endothe-
lial Bcl-xL, but stimulates endothelial proapoptotic pathways, 
in particular, p38-mitogen-activated protein  kinase–mediated 
activation of the proapoptotic Bcl-2 protein tBid.28 Because 
the antiapoptotic effects of healthy HDL in endothelial cells 
persisted after inhibition of eNOS and  after delipidation and 
were not fully mimicked by apoA-I or reconstituted HDL, the 
HDL proteome may be importantly involved in the endothe-
lial effects of HDL. HDL proteomic analyses and subsequent 
validations and functional characterizations suggest reduced 
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Figure 3. High-density lipoprotein (HDL) infusion improves 
endothelial function in humans. Acetylcholine-induced forearm 
blood flow in subjects with normal plasma cholesterol levels and 
in hypercholesterolemic subjects before and after infusion with 
reconstituted HDL. Modified and adapted from Spieker et al.66 
Authorization for this adaptation has been obtained both from the 
owner of the copyright in the original work and from the owner of 
copyright in the translation or adaptation.
Figure 4. Mechanisms of altered vascular effects of high-
density lipoprotein (HDL) in coronary disease. Activity of 
paraoxonase-1 (PON-1) is reduced in HDL obtained from 
patients with coronary artery disease. ABCA1 indicates ATP-
binding cassette transporter A1; apoA-I, apolipoprotein A-I; 
eNOS, endothelial NO synthase; LOX1, lectin-like oxidized LDL 
receptor-1; MDA, malondialdehyde; and MPO, myeloperoxidase. 
Modified and adapted from Mineo et al.114 Authorization for 
this adaptation has been obtained both from the owner of the 
copyright in the original work and from the owner of copyright in 
the translation or adaptation. 
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clusterin and increased apo C-III content in HDL-CAD or 
HDL-ACS to be potential mechanisms (Figure 5).28
HDL as a Therapeutic Target
Based on the inverse epidemiological relation of HDL-C plas-
ma levels with major adverse cardiovascular events, HDL-C 
has been considered an attractive therapeutic target. As a con-
sequence, several drugs to raise HDL-C have been developed 
and investigated at basic and clinical levels. The first class of 
drugs that became available was the fibrates, which mark-
edly lower plasma triglyceride levels and modestly increase 
HDL-C. Unfortunately, most trials with fibrates, particularly 
those performed recently, have yielded no or only minimal 
cardiovascular benefits with this class of drugs.7,80
Peroxisome proliferator-activated receptor-γ agonists 
such as rosiglitazone and pioglitazone are also able to in-
crease HDL-C plasma levels in patients at risk or with 
CAD. Unfortunately, large outcome trials have yielded 
only minimal prognostic benefit with these drugs in this 
patient population.81–84 Furthermore, it seemed that peroxi-
some  proliferator-activated receptor-γ agonists increase 
the incidence of heart failure because of fluid retention.85,86 
Rosiglitazone has, therefore, been withdrawn from the 
market.87 Pioglitazone has not been widely accepted by 
the cardiovascular community, and the US Food and Drug 
Admnistration has recently published a safety announcement 
related to its potential cancer risk.
Niacin is a hypolipidemic drug that has been used since 
the 1970s to treat patients with hyperlipidemia. Although 
its mechanism of action remains unclear,88 niacin increases 
HDL-C by between 15% and 30% and lowers LDL-C and 
particularly triglycerides. The ARBITER 6-HALTS (Arterial 
Biology for the Investigation of the Treatment Effects of 
Reducing Cholesterol 6—HDL and LDL Treatment Strategies 
in Atherosclerosis) trial showed that niacin not only favorably 
modified lipid profiles, but also reduced plaque formation in 
carotid and coronary arteries.89 Unfortunately, the large out-
come trial AIM-HIGH (Atherothrombosis Intervention in 
Metabolic Syndrome with Low HDL/High Triglycerides), 
supported by the National Institutes of Health, was stopped 
 after a little more than 3000 patients had been recruited, be-
cause of futility.9 The trial has been criticized for its small 
sample size and the fact that the dose of simvastatin (which 
was used as background therapy to control LDL-C) had been 
adapted to the LDL levels achieved with either placebo or nia-
cin. Thus, patients on niacin received lower dosages of statin 
compared with patients on placebo, which can make the inter-
pretation of the results challenging.
Big hopes rested on the Heart Protection Study 
2—Treatment of HDL to Reduce the Incidence of Vascular 
Events (HPS-THRIVE) trial, which investigated the effect of 
 extended-release niacin in combination with laropiprant (a 
prostaglandin D2 receptor antagonist to reduce the  incidence 
of flushing) in addition to simvastatin in 25 673 patients at 
high cardiovascular risk.90,91 No significant benefit of the nia-
cin–laropiprant combination on the primary outcome of major 
vascular events was seen when added to effective statin-based 
LDL-lowering therapy. Even worse, serious adverse events, 
such as diabetic complications and new onset diabetes mel-
litus as well as infections due to known and unrecognized 
Figure 5. Proteins in high-density lipoprotein (HDL) from healthy subjects and patients with coronary artery disease (CAD) 
were identified and quantified using spectral index, and data are presented as proteins reduced or enriched in HDL-CAD. Gene 
ontology analysis suggested that changes in clusterin and apolipoprotein CIII are relevant for altered effects of HDL-CAD on endothelial 
apoptosis, which was also validated by further studies. Modified and adapted from Riwanto et al.28 Authorization for this adaptation has 
been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation. 
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off-target effects of niacin (or laropiprant), became apparent. 
Moreover, the risk of myopathy was increased by adding the 
niacin–laropiprant combination to simvastatin 40 mg daily 
(with or without ezetimibe), particularly in Chinese patients 
whose myopathy rates on simvastatin were higher.90
Inhibition of CETP
The most potent novel class of HDL-C–increasing drugs is 
CETP inhibitors.92 CETP is a plasma protein promoting the 
transfer of cholesterol esters from HDL to LDL (Figure 6). 
CETP inhibitors reduce the transfer of cholesterol esters in 
between different HDL particles, that is, from HDL2 to HDL3, 
and from HDL to very low-density lipoproteins or LDL, and 
thereby produce marked and consistent elevations of plasma 
HDL-C levels between 30% to 140%.93 When added to a 
high dose of a statin, LDL-C either remains unchanged (for 
instance, with dalcetrapib) or decreases further ≈40% (with 
torcetrapib, anacetrapib, or evacetrapib).
In the large ILLUMINATE (Investigation of Lipid Level 
Management to Understand Its Impact in Atherosclerotic 
Events) trial involving 15 067 high-risk patients, the addition 
of torcetrapib to 80 mg of atorvastatin was found to be associ-
ated with increased mortality and morbidity.8 This finding was 
particularly surprising because HDL-C increased by 80% and 
LDL-C decreased by 25% as compared with atorvastatin alone.8 
Interestingly, in the RADIANCE 2 (Rating Atherosclerotic 
Disease Change by Imaging with a New Cholesteryl-Ester-
Transfer Protein Inhibitor) trial,94 which used B-mode carot-
id ultrasound, as well as in the  Investigation of Lipid Level 
Management Using Coronary Ultrasound to Assess Reduction 
of Atherosclerosis by CETP Inhibition and HDL Elevation 
(ILLUSTRATE) trial,95 which used coronary intravascular 
ultrasound, torcetrapib did not reduce carotid intima-media 
thickness, nor did it decrease coronary plaque volume, despite 
favorable changes in the lipid profile. These unfavorable out-
comes are likely related to off-target effects, such as increase 
in blood pressure and endothelial dysfunction. Although the 
blood pressure increase is likely related to increased aldoste-
rone secretion from adrenal glands,96,97 the vascular effects are 
due to the suppression of eNOS as well as increased release of 
reactive oxygen species and of endothelin-1.98 Because such 
effects also occur in animals lacking CETP, such as rodents, 
they are likely off-target effects specific to this molecule.
Novel CETP Inhibitors
Subsequently, other CETP inhibitors such as anacetrapib, dal-
cetrapib, and evacetrapib have been developed, which seem 
to lack the off-target effects of torcetrapib. These compounds 
do not affect aldosterone secretion. In the Determining the 
Efficacy and Tolerability of CETP Inhibition with Anacetrapib 
(DEFINE) trial, anacetrapib was not found to raise blood pres-
sure,100 whereas in the dal-OUTCOMES trial, dalcetrapib was 
found to do so in a minor but statistically significant manner.10 
Furthermore, in the dal-VESSEL trial, dalcetrapib did not im-
pair flow-mediated vasodilation, an index of endothelial func-
tion in humans in vivo.99
In the dal-PLAQUE study,101 the effects of dalcetrapib on 
plaque formation and inflammation in the human carotid 
artery were investigated using MRI and PET technology. The 
results tended to show a small reduction in the increase in to-
tal vessel area, whereas inflammation as measured by fluo-
rodeoxyglucose uptake remained unaffected. However, CRP 
levels were found to be increased by dalcetrapib treatment 
in the dal-OUTCOMES trial.10 By contrast, CRP was unaf-
fected by anacetrapib in DEFINE trial; in fact, it tended to be 
slightly higher in the treatment than in the placebo group.100 
As such, it is not surprising that the dal-HEART program was 
stopped by Roche on May 14, 2012, after an interim analysis 
Figure 6. Schematic representation of high-density 
lipoprotein (HDL) metabolism. HDL metabolism is initiated by 
the secretion of lipid-free apolipoprotein (apoA-I) by the liver 
and intestine. Both hepatocytes and enterocytes express ATP-
binding cassette (ABC) transporter A1 (ABCA1), which effluxes 
phospholipids and cholesterol and thereby lipidates apoA-I 
extracellularly. Lipid-free apoA-I is also generated by the lipolysis 
of triglyceride-rich lipoproteins (TGRL; chylomicrons and very 
low-density lipoprotein [VLDL]) and the interconversion of HDL 
subclasses in the course of lipolysis and lipid transfer and then 
interacts with ABCA1 in liver and peripheral cells. The resulting 
nascent HDL discs induce cholesterol efflux from macrophages 
by mechanisms involving ABCG1 and scavenger receptor BI 
(SR-BI). Lecithin/cholesterol acyltransferase (LCAT)-mediated 
cholesterol esterification turns the discoidal HDL into mature 
spherical particles. The initially smaller HDL3 particles grow in 
size by ongoing lipid efflux, cholesterol esterification, and fusion 
with HDL and surface remnants of TGRL through phospholipid 
transfer protein (PLTP). The resulting HDL2 particles deliver lipids 
to the liver, either directly via HDL receptors or indirectly via lipid 
transfer to LDL, which are then internalized by the LDL receptor 
pathway. In the direct pathway, SR-BI mediates the selective 
uptake of cholesteryl esters into hepatocytes. In addition to this 
nonendocytic pathway, an as-yet-unknown HDL receptor, which 
is stimulated by the interaction of apoA-I with ectopic β-ATPase 
and the subsequently activated P2Y13 receptor, mediates 
holoparticle uptake. The indirect pathway requires the exchange 
of cholesteryl esters and triglycerides between HDL and VLDL, 
which is mediated by the cholesteryl ester transfer protein 
(CETP). Reverse cholesterol transport is finalized by the biliary 
excretion of cholesterol from the liver into the intestine either 
directly via ABCG5 and ABCG8 or after cytochrome P enzyme 
(CYP7α)-mediated oxidation to bile acids via the bile salt export 
pump ABCB11. The actions of SR-BI, CETP, hepatic lipase (HL), 
and endothelial lipase (EL) on HDL2, as well as of PLTP on HDL3, 
lead to the interconversion of HDL particles and also liberate 
lipid-free apoA-I, which is either used for de novo formation of 
mature HDL particles or filtrated through the renal glomeruli for 
tubular uptake and degradation (red dotted arrows). Blue arrows 
indicate lipid transfers; and red arrows, protein or holoparticle 
tranfers. Modified and adapted from von Eckardstein.11 
Authorization for this adaptation has been obtained both from the 
owner of the copyright in the original work and from the owner of 
copyright in the translation or adaptation. 
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of dal-OUTCOMES showed absolutely no benefit of dalcetra-
pib compared with placebo in patients after ACS.10 Of note, 
the clinical outcome was precisely predicted by the results of 
the endothelial function study dal-VESSEL, suggesting that 
changes in flow-mediated vasodilation are a reliable surrogate 
end point in predicting treatment effects in high-risk patients.
The metabolic effects of the novel CETP inhibitors, howev-
er, differ: whereas dalcetrapib selectively increases HDL-C by 
only ≈30% and apoA-I by ≈18%, with LDL-C and ApoB-100 
levels unaffected,99 anacetrapib and evacetrapib have marked 
effects on LDL-C as well. The neutral effects of dalcetrapib 
may be related to the fact that a 30% increase in HDL-C may 
not be enough to alter endothelial function and clinical out-
come in patients at risk. Moreover, HDL in patients with ACS 
may be dysfunctional and hence unable to exert protective ef-
fects when therapeutically raised.
In contrast, anacetrapib increases HDL-C by ≈140% and 
lowers LDL-C by 40% beyond the levels achieved with ator-
vastatin, as shown in the DEFINE trial100; this compound 
may improve outcome, hypothesizes the large REVEAL 
(Randomized Evaluation of the Effects of Anacetrapib 
Through Lipid Modification) trial, which is currently recruit-
ing high-risk patients with a history of ACS, peripheral arterial 
or cerebrovascular disease, or diabetes mellitus.102
ApoA-I Mimetic Peptides
ApoA-I contains 243 amino acids. Peptides with only 18 
amino acids that are not homologous to those in apoA-I, but 
which mimic the distribution of charge and structure of por-
tions of apoA-I, were found to render HDL anti-inflammatory 
(as measured in an in vitro assay) and significantly reduce 
inflammation in several animal models of disease, including 
atherosclerosis.103 Based on these preclinical studies, 2 small 
clinical trials were conducted. In the first trial, the apoA-I 
mimetic peptide was administered orally in doses from 0.43 
to 7.14 mg/kg. The plasma levels achieved were very low (a 
maximum of ≈16 ng/mL). Peptide doses of 4.3 and 7.14 mg/kg 
significantly improved a measure of HDL functionality, the 
HDL inflammatory index; however, doses of 0.43 and 1.43 
mg/kg did not.104
Because the therapeutic agent was an apoA-I mimetic pep-
tide and the goal was to improve the function of a plasma 
lipoprotein (HDL), it was assumed that the peptide acted in 
the plasma, and plasma levels were a critical success factor. 
Therefore, the next trial targeted plasma peptide levels using 
low doses (0.042–1.43 mg/kg; doses that were ineffective in 
the first trial) but were administered intravenously or subcu-
taneously to achieve high plasma levels. High plasma levels 
were achieved (≈3250 ng/mL), but there was no improvement 
in the HDL inflammatory index.105
To understand these perplexing results, mice studies were 
performed. Surprisingly, when equal doses of peptide were 
administered, peptide levels were similar in the tissue of the 
small intestine, whether the peptide was administered orally 
or subcutaneously, but this was not the case in plasma or in 
liver where the plasma and liver levels, respectively, were 100- 
and 1000-fold higher after administering the peptide subcu-
taneously compared with orally. Efficacy as measured by the 
HDL inflammatory index, serum amyloid A levels, plasma ly-
sophosphatidic acid levels, or by the extent of atherosclerotic 
lesions were identical at each dose regardless of the route of 
administration or the plasma peptide levels. At each dose, the 
concentration and amount of peptide in the feces were equal 
regardless of the route of administration or the plasma levels. 
It was concluded that (1) the dose of peptide administered, and 
not the plasma level, determined efficacy, and (2) the intestine 
is a major site of action for the peptide regardless of the route 
of administration.106
In a subsequent study, the administration of the same dose 
of peptide similarly reduced a large number of oxidized me-
tabolites of arachidonic acid in small intestine enterocytes, 
whether the peptide was administered orally or subcutane-
ously, despite the 100- to 1000-fold greater liver and plasma 
levels of peptide after administration of the peptide subcutane-
ously compared with orally. These oxidized metabolites were 
significantly reduced to an even greater extent in liver and 
were not different whether peptide was administered subcuta-
neously or orally. Because the plasma and liver concentrations 
of peptide after administering the peptide orally were 100- to 
1000-fold lesser compared with administering the peptide 
subcutaneously, these data strongly suggest that the reduction 
of oxidized metabolites of arachidonic acid in the small intes-
tine by the peptide led to the reduction in liver levels.107
These results likely explain the failure of the clinical trial 
by Watson et al.105 The dose administered was likely too low 
to achieve the needed peptide levels in the small intestine. The 
results also suggest that a dose of peptide on the order of 40 to 
100 mg/kg per day will be required for efficacy. The 4F pep-
tide used in the clinical trials requires chemical end groups 
so as to be efficient. These end groups can only be added 
by chemical synthesis, making 4F at such doses too costly 
for clinical use.108,109 To overcome this problem, a search 
was conducted to find an apoA-I mimetic peptide that did 
not require these end groups for efficacy, and the peptide 6F 
was identified. The 6F peptide was transgenically expressed 
in tomatoes, freeze-dried, ground into powder, and added at 
2.2% by weight to a Western diet to be fed to LDL recep-
tor null mice.109 The mice receiving transgenic 6F tomatoes 
had lower plasma levels of serum amyloid A, total choles-
terol, and triglycerides compared with mice fed with control 
tomatoes. Levels of unsaturated lysophosphatidic acid were 
reduced in the tissue of the small intestine and in the plasma 
of mice fed with transgenic 6F tomatoes. Importantly, plasma 
HDL-C and PON-1 activity increased in the mice receiving 
tomatoes with 6F peptide, and aortic atherosclerosis reduced 
≈50% compared with control mice. The levels of unsaturated 
lysophosphatidic acid in the tissue of the small intestine cor-
related with the percent of aorta with atherosclerotic lesions. 
Hours after the mice finished eating transgenic 6F tomatoes, 
intact peptide was found in the small intestine, but no pep-
tide was found in the plasma, suggesting that the peptide was 
acting in the intestine and not in the plasma. It is tempting 
to speculate that the concentration of unsaturated lysophos-
phatidic acid and oxidized lipids in the small intestine is the 
target for apoA-I mimetic peptides, and the small intestine 
concentration of these lipids determines their concentration 
in liver and plasma.106–109,111
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The recent work of Navab et al112,113 is consistent with this 
hypothesis. They found that feeding LDL receptor null mice a 
high-fat, high-cholesterol Western diet increased unsaturated 
(but not saturated) lysophosphatidic acid levels in the small in-
testine and caused changes in small intestine gene expression. 
They showed that the addition of transgenic tomatoes express-
ing the apoA-I mimetic peptide 6F to the Western diet pre-
vented many Western diet–mediated small intestine changes in 
gene expression. If, instead of feeding the Western diet, un-
saturated lysophosphatidic acid was added to the low-fat chow 
diet and fed to the mice, the levels of lysophosphatidic acid in 
the small intestine were similar to those induced by feeding the 
Western diet.112 They found that gene expression changes in the 
small intestine after the addition of unsaturated lysophospha-
tidic acid to the low-fat chow diet mimicked the changes seen 
after feeding the Western diet and also mimicked the changes 
in plasma serum amyloid A, total cholesterol, triglycerides, 
HDL-C, and lipoprotein profiles seen after feeding the Western 
diet. Adding freeze-dried tomato powder from tomatoes trans-
genic for the 6F peptide (but not from control tomatoes) to the 
lysophosphatidic acid–supplemented low-fat chow diet pre-
vented the lysophosphatidic acid–induced changes.112 It was 
concluded that (1) Western diet–mediated systemic inflam-
mation and dyslipidemia may be, in part, because of Western 
diet–induced increases in small intestine lysophosphatidic acid 
levels, and (2) transgenic tomatoes expressing the 6F peptide 
reduce Western diet–mediated systemic inflammation and dys-
lipidemia by preventing Western diet–induced increases in ly-
sophosphatidic acid levels in the small intestine.112
These studies demonstrate the complexity of HDL and 
its proteins and suggest that the small intestine, which pro-
duces ≈30% of plasma HDL in mice,110 may be particu-
larly important in regulating HDL function and systemic 
inflammation.108,109,111–113
Perspective
Although HDL-C is a very promising marker and potential 
therapeutic target based on its epidemiological data and the 
effects of healthy HDL in vitro in endothelial cells and mac-
rophages, as well as based on infusion studies of reconstituted 
HDL in patients with hypercholesterolemia, it still remains 
uncertain whether or not HDL-C–raising drugs will become 
part of our preventive armamentarium in the future. Recent 
studies found that HDL got modified in patients with CAD or 
ACS because of oxidative processes and alterations in its com-
position (proteome and lipidome/metabolome remodelling), 
leading to HDL dysfunction. Therefore, it will be important to 
demonstrate that novel drugs not only increase HDL-C plasma 
levels but also improve HDL function114 in patients at high 
cardiovascular risk.
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